Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients with NAMD (phase I Portion)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06672536
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients With Advanced Malignant Solid Tumours.
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 441
- Registration Number
- NCT06600022
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06318884
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 515
- Registration Number
- NCT06304818
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT06252298
- Locations
- 🇨🇳
Beijing Chaoyang Hospital ,Capital Medical University, Beijing, Beijing, China
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06197009
- Locations
- 🇹🇷
Hacettepe University Faculty of Medicine, Ankara, Hacettepe Mh., Turkey
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 18000
- Registration Number
- NCT06041061
- Locations
- 🇨🇳
Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
🇨🇳Shanxi Center for Disease Control and Prevention, Taiyuan, Shanxi, China
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05933512
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05894707
- Locations
- 🇦🇺
Linear Clinical Research - Harry Perkins, Nedlands, Western Australia, Australia
🇦🇺Linear Clinical Research - Joonadalup, Joondalup, Western Australia, Australia
🇦🇺Linear Clinical Research - B Block, Nedlands, Western Australia, Australia
Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023
- Conditions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 20000
- Registration Number
- NCT05758675
- Locations
- 🇨🇳
Dazhu County Center for Disease Control and Prevention, Dazhou, Sichuan, China